Zydus Therapeutics reports positive phase-3 results in rare liver disease
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
Guidelines aim to establish state-regulated veterinary blood banks
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
Inclacumab was generally well tolerated in THRIVE-131
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
Subscribe To Our Newsletter & Stay Updated